Format
Sort by

Send to:

Choose Destination

Search results

Items: 5

1.

Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.

Knip M, Åkerblom HK, Becker D, Dosch HM, Dupre J, Fraser W, Howard N, Ilonen J, Krischer JP, Kordonouri O, Lawson ML, Palmer JP, Savilahti E, Vaarala O, Virtanen SM; TRIGR Study Group.

JAMA. 2014 Jun 11;311(22):2279-87. doi: 10.1001/jama.2014.5610.

2.

Recruitment and retention of participants for an international type 1 diabetes prevention trial: a coordinators' perspective.

Franciscus M, Nucci A, Bradley B, Suomalainen H, Greenberg E, Laforte D, Kleemola P, Hyytinen M, Salonen M, Martin MJ, Catte D, Catteau J; TRIGR Investigators.

Clin Trials. 2014 Apr;11(2):150-8. doi: 10.1177/1740774513510070. Epub 2013 Nov 11.

3.

Use of vitamin D supplements during infancy in an international feeding trial.

Lehtonen E, Ormisson A, Nucci A, Cuthbertson D, Sorkio S, Hyytinen M, Alahuhta K, Berseth C, Salonen M, Taback S, Franciscus M, González-Frutos T, Korhonen TE, Lawson ML, Becker DJ, Krischer JP, Knip M, Virtanen SM; TRIGR Investigators.

Public Health Nutr. 2014 Apr;17(4):810-22.

4.

Growth differences between North American and European children at risk for type 1 diabetes.

Nucci AM, Becker DJ, Virtanen SM, Cuthbertson D, Softness B, Huot C, Wasikowa R, Dosch HM, Akerblom HK, Knip M; TRIGR Study Group.

Pediatr Diabetes. 2012 Aug;13(5):425-31. doi: 10.1111/j.1399-5448.2011.00840.x. Epub 2012 Jan 17.

5.

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.

Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R; NBI-6024 Study Group.

Diabetes Care. 2009 Nov;32(11):2036-40. doi: 10.2337/dc09-0449. Epub 2009 Aug 18.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk